Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.6891
+0.0041 (0.60%)
At close: May 8, 2025, 4:00 PM
0.6862
-0.0029 (-0.42%)
Pre-market: May 9, 2025, 7:28 AM EDT
Lexicon Pharmaceuticals Stock Forecast
LXRX's stock price has decreased by -61.07% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Lexicon Pharmaceuticals stock have an average target of 3.67, with a low estimate of 1.00 and a high estimate of 6.00. The average target predicts an increase of 432.58% from the current stock price of 0.69.
Analyst Consensus: Buy
* Price targets were last updated on Mar 28, 2025.
Analyst Ratings
The average analyst rating for Lexicon Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +480.47% | Mar 28, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $6 | Buy | Maintains | $10 → $6 | +770.70% | Mar 7, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +480.47% | Mar 7, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $1 | Buy → Hold | Downgrades | $1 | +45.12% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
10.66M
from 31.08M
Decreased by -65.71%
Revenue Next Year
19.70M
from 10.66M
Increased by 84.78%
EPS This Year
-0.38
from -0.63
EPS Next Year
-0.34
from -0.38
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.2M | 38.2M | 86.2M | ||
| Avg | 10.7M | 19.7M | 56.8M | ||
| Low | n/a | 9.9M | 28.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -25.3% | 258.6% | 337.7% | ||
| Avg | -65.7% | 84.8% | 188.6% | ||
| Low | - | -7.1% | 46.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.37 | -0.21 | -0.11 | ||
| Avg | -0.38 | -0.34 | -0.30 | ||
| Low | -0.39 | -0.46 | -0.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.